A novel syndrome in the FANCM gene caused by biallelic mutations predisposes the body to tumors and rejection to chemotherapy.
Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
In this editorial find out about the promises and limitations of gemcitabine monotherapy as an adjuvant chemotherapy in pancreatic adenocarcinoma.
A study has indicated that patients with advanced inoperable stage 3 lung cancer can benefit from an improved rate of survival when undergoing concurrent chemotherapy and proton therapy.
A novel global study has set a risk-based standard in order to personalize chemotherapy for colon cancer following surgery.
Researchers identify a novel way to target chemo-resistance leukaemia cells – an interview with Peter Stern
Listen to this exclusive interview with Peter Stern (University of Manchester, UK) to discover more about chemotherapy resistance in acute lymphoblastic leukemia and novel strategies to overcome it.
A group of researchers have uncovered a link between chemo-resistance in pediatric acute lymphoblastic leukaemia and the protein 5T4; early-testing indicates that targeting the protein could help improve treatment outcomes.
This article provides a immunotherapy perspective of Ipilimumab, a CTLA-4-targeted monoclonal antibody, reviewing drug mechanism, blockade, combination therapies and future prospectives.
Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?
This article summarizes the outcome of a randomized phase III clinical trial investigating the effect of FLT3 inhibitors to improve FTL3-mutated acute myeloid leukemia
Frequent alterations of homologous recombination repair pathway in primary and chemotolerant breast carcinomas: clinical importance
This article outlines the importance of homologous recombination repair pathway in development of breast carcinoma (BC), and the influence of gene alterations in chemotherapy treated BC samples.
What are the current limitation with clinical trials for AML? This review discusses trial end points, patient enrollment, cost of drug discovery and patient heterogeneity and future treatment of AML.